Chris Newman

Chris Newman has extensive work experience in various roles within the pharmaceutical and healthcare industry. Chris is currently serving as the Senior Director of Business Development & Alliance Management at FibroGen, Inc. Prior to this, they held the position of Director of Alliances and Business Analytics, Business Development at the same company.

Before joining FibroGen, Inc., Chris worked as a Senior Consultant at Promidian, specializing in business development, strategic alliance advisory, payer strategy, competitive landscaping, and commercial and financial planning. Chris was also responsible for forecasting and data analytics, using their quantitative modeling skills to develop payer, forecasting, and database models.

Chris has previous experience at GSK, where they served as a Finance Manager. In this role, they led projects related to investment rationale and strategy for new products and provided financial support to senior members of Commercial teams. Chris also played a key role in managing relationships and communication between the Finance and Commercial teams, as well as other internal partners.

Prior to GSK, Chris worked as an Associate Intern in Business Development at West Health and held positions at Barclays Bank as an Assistant Vice-President in Structured Finance and as an Analyst in Healthcare. Chris also has experience as a Doctor in the NHS.

Overall, Chris Newman's work experience demonstrates their expertise in business development, alliance management, financial planning, and strategic decision-making within the pharmaceutical and healthcare industry.

Chris Newman has an impressive education history with a focus on healthcare, finance, and medicine. From 2011 to 2013, they attended Yale University, earning a Master of Business Administration (MBA) degree with a specialization in healthcare and finance. Prior to that, from 2001 to 2007, Chris studied at King's College London, where they obtained a Doctor of Medicine (M.D.) degree in medicine. Additionally, in 2003 to 2004, they completed a BSc degree in Medical Technology at the same institution.

In terms of additional certifications, Chris obtained the Chartered Financial Analyst (CFA) Charterholder designation from the CFA Institute in April 2014. Chris also completed the BIO Professional Development Courses in November 2022, offered by the Biotechnology Innovation Organization (BIO).